In today's digital landscape, misinformation about health is rampant, often leading individuals to make ill-informed decisions regarding their well-being. A recent article from The Brit Factor highlights the alarming trend of patients turning to unverified online sources, sometimes opting for surgical interventions without exploring conservative treatments like physical therapy. Discover how doctors can leverage digital platforms to combat misinformation, build trust, and guide patients toward informed health decisions.

In this episode, we explore eight pivotal developments in the orthobiologics arena that are transforming spine care and regenerative medicine. From innovative partnerships to FDA clearances, these stories highlight the dynamic advancements shaping patient outcomes and clinical practices.

In this episode, we delve into the pivotal role of fusion rate in spinal interbody fusion procedures.

In this groundbreaking episode, we delve into a pioneering clinical trial that aims to revolutionize the treatment of spinal cord injuries (SCI). Led by Professor James St John at Griffith University's Clem Jones Centre for Neurobiology and Stem Cell Research, the study introduces an innovative approach combining olfactory ensheathing cells (OECs) with intensive rehabilitation to restore motor, sensory, and autonomic functions in individuals with SCI.

In this episode, we delve into the recent FDA warning letter issued to Globus Medical concerning its ExcelsiusGPS surgical robot system. While the FDA did not mandate a product recall, the letter highlights significant concerns regarding the company's internal processes for handling complaints and quality control.

In this episode, we delve into the recent patent infringement lawsuit filed by Spinelogik against Camber Spine Technologies. The dispute centers on Camber's SPIRA®-C cervical interbody fusion device, which Spinelogik alleges infringes upon U.S. Patent No. 8,460,385. This patent pertains to technology designed to promote spinal fusion by delivering and anchoring a fusion member between vertebral bodies.

In this episode of The Brit Factor, we delve into the alarming case of Tina Langford, who contracted tuberculosis following a spinal surgery involving the FiberCel Fiber Viable Bone Matrix. This product, manufactured by Elutia (formerly Aziyo Biologics), was linked to a 2021 outbreak that prompted an FDA recall after multiple patients developed TB infections.

In this episode, we delve into a compelling article from the Global Spine Journal that scrutinizes ten significant cost drivers in spine surgery. These factors often inflate healthcare expenses without delivering proportional benefits to patients.